Benzodiazepine

• 1. Introduction

  ›

  Benzodiazepines are a class of drugs that, by 1977, had become the most prescribed medications on the entire planet. That rise happened with remarkable speed. A chemist named Leo Sternbach was working at Hoffmann-La Roche in 1955 when he accidentally synthesized a compound he then set aside and largely forgot. Two years later, his co-worker Earl Reeder was spring-cleaning the lab and noticed what he described as a "nicely crystalline" compound left over from the abandoned project. That discovery, eventually named chlordiazepoxide and marketed as Librium, opened a new era in psychiatry. Within a few years it was joined by diazepam, sold under the name Valium. Together they replaced a whole prior generation of sedative drugs. But the story of benzodiazepines is not simply one of medical progress. It is also a story about dependence, about a legal system overwhelmed by 14,000 patients filing claims against drug manufacturers, and about debates that medical bodies are still having today. What are these drugs actually doing inside the brain? What happens when the body tries to stop? And who bears the greatest risk?

• 2. A Accidental Discovery

  ›

  Leo Sternbach was developing tranquilizers for Hoffmann-La Roche when, in 1955, he synthesized chlordiazepoxide. The initial pharmacological results were disappointing, and he moved on to other projects. The compound sat untested for two years, until Earl Reeder spotted it during a lab clean-up in April 1957. Researchers submitted it for a standard battery of animal tests, expecting little. Instead the compound showed what the source describes as "very strong sedative, anticonvulsant, and muscle relaxant effects." Those findings were striking enough to accelerate its development, and Librium reached the market in 1960. Hoffmann-La Roche followed up by developing diazepam, marketed as Valium, in 1963, and for a time both drugs ranked among the most commercially successful pharmaceuticals in the world. Their arrival triggered a significant shift in prescribing habits. Barbiturates, which had dominated sedation and sleep medicine, were progressively displaced throughout the 1970s. The new drugs appeared safer in overdose than their predecessors, and that perception drove rapid adoption. Within a single generation, benzodiazepines had gone from a forgotten lab sample to the most commonly prescribed drug class globally.

• 3. How They Work

  ›

  At the center of how benzodiazepines function is a neurotransmitter called gamma-aminobutyric acid, or GABA. GABA is the brain's primary inhibitory chemical; it reduces neuronal excitability by binding to a protein complex called the GABAA receptor, which sits in the synapses between neurons. When GABA binds to this receptor, it opens a channel that allows negatively charged chloride ions to flow into the neuron. That influx pushes the neuron's membrane potential further from the threshold needed to fire, making it less likely to send a signal. Benzodiazepines do not mimic GABA directly. Instead, they bind to a separate site on the GABAA receptor complex, one that exists only on a subset of receptors that also contain a specific histidine amino acid residue in their alpha subunit. Once bound, they act as what chemists call a positive allosteric modulator: they increase the frequency with which the chloride ion channel opens when GABA is already present. The result is a stronger inhibitory signal without replacing or flooding the system with a new chemical. Different receptor subtypes are distributed differently across the brain, which is why the same drug class can produce sedation, anxiety relief, muscle relaxation, seizure suppression, and memory interference, sometimes all at once. A drug marketed as a sleeping aid at low doses can reduce anxiety, and one marketed for anxiety at higher doses can induce sleep. The receptor subtypes that appear most important for sleep tend to involve the alpha-1 subunit, while those linked to anti-anxiety effects involve alpha-2 and alpha-3 subunits. Beyond the brain, benzodiazepines also interact with peripheral benzodiazepine receptors found in immune cells and the gastrointestinal tract, and they act as weak inhibitors of adenosine reuptake, though these actions are considered secondary.

• 4. The Dependence Problem

  ›

  Tolerance to benzodiazepines does not develop evenly across all their effects. A review cited in the source concluded that tolerance develops relatively quickly for sedative and anticonvulsant actions, while tolerance to anxiolytic and amnesic effects may not develop at all, though the randomized trial evidence supporting that claim extends only to 22 weeks. For sleep, the picture is clearer and grimmer: several studies have confirmed that long-term benzodiazepines are not significantly more effective than placebo for sleep. Tolerance to hypnotic effects can emerge within days to weeks. What remains even as the therapeutic benefits fade is a set of persistent adverse effects, including depression and impulsivity with elevated suicidal risk. Discontinuation is its own challenge. Even after a relatively short course of two to four weeks, stopping can produce two distinct types of symptoms. Rebound symptoms are a return of the original problem, but worse than it was before treatment. Withdrawal symptoms are entirely new: insomnia, gastric disturbance, tremors, agitation, fearfulness, and in severe cases, psychosis, seizures, and a dangerous state called delirium tremens. The underlying mechanism involves the brain compensating for chronic GABA enhancement by increasing activity of the excitatory neurotransmitter glutamate. When the drug is removed suddenly, that compensatory glutamate activity surges without the usual inhibitory counterbalance, a process that can damage nerve cells. The American Society of Addiction Medicine, working with ten other American medical associations, issued guidance in June 2025 stating that tapers should generally reduce doses by 5 to 10% every two to four weeks, and should never exceed 25% reduction every two weeks. A taper that moves too fast, they emphasized, can be life-threatening. About ten percent of patients experience what the source calls a protracted withdrawal syndrome, with symptoms that may persist for many months or in some cases longer than a year.

• 5. Who Bears the Greatest Risk

  ›

  Older adults occupy a particularly vulnerable position with benzodiazepines. The American Geriatrics Society lists all benzodiazepines as potentially inappropriate medications for older adults, a designation formalized in what is known as the Beers List. The elderly are more sensitive to the drugs' adverse effects across the board: memory problems, daytime sedation, impaired motor coordination, increased likelihood of traffic accidents, and a doubled incidence of falls and hip fractures. Long-term use can produce effects that resemble dementia, depression, or anxiety disorders, and these effects may be attributed incorrectly to aging itself rather than to the medication. The good news documented in the source is that withdrawal in this group can yield genuine improvements: better cognition, alertness, and mobility, along with reduced incidence of falls and incontinence. For pregnant people, the picture is different but also concerning. The US Food and Drug Administration placed benzodiazepines in either category D or X, meaning demonstrated potential for harm to the unborn. Exposure during pregnancy has been linked to a slightly increased risk of cleft palate, moving from roughly 0.06% to 0.07%, though some studies find no association. Use shortly before delivery may produce what the source calls floppy infant syndrome, in which newborns show abnormally low muscle tone, hypothermia, lethargy, and breathing difficulties. Neonatal withdrawal syndrome can also occur, and may not appear until several days after birth; in the case of chlordiazepoxide, symptoms have appeared as late as 21 days after delivery and may persist for three to six months.

• 6. Legal Battles and Regulatory Shift

  ›

  In the 1980s, growing evidence of dependence in ordinary patients set off what the source describes as the largest-ever class-action lawsuit against drug manufacturers in the United Kingdom. The case involved 14,000 patients and 1,800 law firms, who alleged that manufacturers had known about the dependence potential and had intentionally withheld that information from doctors. Simultaneously, 117 general practitioners and 50 health authorities were sued separately by patients seeking to recover damages. The drug manufacturer case never reached a verdict. Legal aid was withdrawn, and questions arose about conflicts of interest among the expert psychiatric witnesses. The case collapsed at a cost of £30 million, and that outcome made future class-action cases harder to pursue by raising the financial stakes for any individual suing after losing. Some doctors, in response to the controversy, began requiring signed consent forms and committed to warning all patients about dependence and withdrawal risks before prescribing. At the regulatory level, the shift came more gradually. In September 2020, the US Food and Drug Administration required updated boxed warnings for all benzodiazepine medicines, mandating that packaging describe the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions consistently across the entire drug class. Internationally, benzodiazepines sit in Schedule IV under the Convention on Psychotropic Substances, with one exception: flunitrazepam, which is classified as Schedule III.

• 7. Recreational Use and Public Harm

  ›

  Non-medical benzodiazepine use is closely linked to broader patterns of polysubstance use. A survey of detainees conducted by Australian police between 1999 and 2005 found that self-reported benzodiazepine users were more likely than non-users to use methamphetamine or heroin, and less likely to be working full-time. Mortality is higher among polysubstance users who also take benzodiazepines, and the combination with alcohol sharply raises that risk. Combining benzodiazepines with alcohol, opioids, or tricyclic antidepressants intensifies sedation and respiratory depression, and the pairing can be fatal. The drug temazepam appears to carry particular risk in recreational contexts. The source notes that non-medical temazepam use reached epidemic levels in parts of Europe and Australia, and that it became a major addictive substance in several Southeast Asian countries. Some countries, including Sweden, banned it outright. British law requires temazepam to be stored in double-locked steel safety cabinets, maintained in a written register in ink with no correction fluid, and disposed of only in the presence of a designated inspector. When benzodiazepines are injected intravenously, which does sometimes occur recreationally, the risks extend beyond overdose to include abscesses, deep vein thrombosis, and gangrene, as well as transmission of hepatitis and HIV through shared needles. The College of Physicians and Surgeons of British Columbia has recommended discontinuing benzodiazepines in patients already on opioids, a position that reflects the compounding danger when two classes of central nervous system depressants are combined.